参麦注射液联合阿魏酸钠对急性心肌梗死患者梗死面积及相关指标的影响
x
请在关注微信后,向客服人员索取文件
篇名: | 参麦注射液联合阿魏酸钠对急性心肌梗死患者梗死面积及相关指标的影响 |
TITLE: | |
摘要: | 目的:探讨参麦注射液联合阿魏酸钠对急性心肌梗死患者梗死面积及相关指标的影响。方法:110例急性心肌梗死患者随机分为对照组(55例)和观察组(55例)。对照组患者给予吸氧、硝酸酯类药物扩冠脉、调节水电解质和酸碱平衡、纤溶剂溶血栓、镇痛剂镇静止痛等常规治疗,同时给予参麦注射液50 ml,加入5%葡萄糖注射液200 ml中,静脉滴注,每日2次。观察组患者在对照组治疗的基础上给予注射用阿魏酸钠0.2 g,加入5%葡萄糖注射液200 ml中,静脉滴注,每日2次。两组疗程均为14 d。观察两组患者的临床疗效,治疗前后心肌梗死面积、血液流变学指标(全血比黏度、纤维蛋白原、红细胞聚集指数)、心肌酶学指标[同型半胱氨酸(Hcy)、生长停滞特异性基因产物6(Gas6)]水平及不良反应发生情况。结果:观察组患者总有效率显著高于对照组,差异有统计学意义(P<0.05);治疗前,两组患者心肌梗死面积和全血比黏度、纤维蛋白原、红细胞聚集指数及Hcy、Gas6水平比较,差异均无统计学意义(P>0.05)。治疗后,两组患者心肌梗死面积、全血比黏度、纤维蛋白原、红细胞聚集指数低于同组治疗前,且观察组低于对照组;治疗第8天观察组患者血清Hcy水平,治疗第15天观察组患者血Hcy、Gas 6及对照组患者血清Hcy水平显著低于同组治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05)。两组患者治疗期间均未见明显不良反应发生。结论:在常规治疗的基础上,参麦注射液联合阿魏酸钠治疗急性心肌梗死疗效显著,可降低患者Hcy、Gas6水平,改善血液流变学指标,缩小心肌梗死面积,且安全性较好。 |
ABSTRACT: | OBJECTIVE: To investigate the effects of Shenmai injection combined with sodium ferulate on infarct size and related indicators of patients with acute myocardial infarction. METHODS: 110 patients with acute myocardial infarction were randomly divided into control group(55 patients) and observation group(55 patients). Patients in the control group received oxygen inhalation, coronary expansion by nitrates, water and electrolyte regulation and acid-base balance regulation, thrombolytic fibrinolytic agent utilization, sedation and analgesia by analgesics and other conventional treatments. Meanwhile,50 ml Shenmai injection was given to the control group, dissolved in 200 ml 5% Glucose injection, intravenously, twice a day; observation group was additionally given 0.2 g Sodium ferulate for injection, dissolved in 200 ml 5% Glucose injection, intravenously, twice a day. The treatment course for both groups was 14 d. Clinical efficacy in 2 groups was observed, myocardial infarction size before and after treatment was recorded, hemorheology indexes (whole blood viscosity, fibrinogen and erythrocyte aggregation index), catdiac enzymes index homocysteine (Hcy), and growth arrest-specific gene product 6 (Gas6) before and after treatment together with the incidence of adverse reactions were detected. RESULTS: The total effective rate in observation group was significantly higher than it in control group. The difference was statistically significant (P<0.05); before treatment, there were no statistically significant differences in the myocardial infarction size, hole blood viscosity, fibrinogen, erythrocyte aggregation index, and blood level of Hcy and Gas6 (P>0.05). After treatment, the myocardial infarct size in 2 groups was reduced, hole blood viscosity, fibrinogen and erythrocyte aggregation indexes were reduced, and these in observation group were lower than in control group; in the 8 day during the treatment, serum level of Hcy in observation group was reduced; in the 15 day, blood level of Hcy and Gas6 in observation groups was reduced, serum level of Hcy in control group was reduced, and these in observation group was lower than in control group. The differences were statistically (P<0.05). And there were no obvious adverse reactions during treatment. CONCLUSIONS: Based on conventional treatment, Shenmai injection combined with sodium ferulate shows significant efficacy in the treatment of acute myocardial infarction, and can reduce blood level of Hcy and Gas6, improve hemorheology indexes and narrow the myocardial infarct size. |
期刊: | 2016年第27卷第18期 |
作者: | 李杰华 |
AUTHORS: | LI Jiehua |
关键字: | 阿魏酸钠;参麦注射液;急性心肌梗死;同型半胱氨酸;生长停滞特异性基因产物6 |
KEYWORDS: | Sodium ferulate; Shenmai injection; Acute myocardial infarction; Hcy; Gas6 |
阅读数: | 625 次 |
本月下载数: | 2 次 |
* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!